CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for NewcelX AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

NewcelX AG
The Circle 6
Phone: +41 445122150p:+41 445122150 ZUERICH, 8058  Switzerland Ticker: NCELNCEL
Business Summary
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
8049 Offices and clinics of health practitioners, not elsewhere classified
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board RonaldHafner 61 8/1/2015 8/1/2015
Chief Executive Officer, Director AlexanderZwyer 56 8/1/2015 8/1/2015
Chief Financial Officer NicoleFernandez-mcgovern 52 10/1/2024 10/1/2024
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Kadimastem Ltd Pinchas Sapir 7, Weizmann Science Park NESS-ZIONA Israel

Business Names
Business Name
Kadimastem Ltd
NCEL
NLS Pharma Ltd.
4 additional Business Names available in full report.

General Information
Number of Employees: 1 (As of 5/15/2025)
Outstanding Shares: 4,558,378 (As of 10/31/2025)
Shareholders: 28
Stock Exchange: NASD
Fax Number: +41 445122151


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 6, 2025